Oligomycins belong to the class of highly functionalized macrolide antibiotics that contain the hydroxyl groups, the lactone and spiro moieties, as well as the double bonds. The mechanism of cytocidal activity of oligomycins involves the inhibition of oxidative phosphorylation by preventing ATP synthesis. Design of new compounds on oligomycin A scaffold is of interest as ATP synthase inhibitors are drug candidates for the treatment of bacterial infections and cancer. 1 Recently, we reported the examples of modification at the C 7 carbonyl group and the C 2 ¼C 3 double bond of the antibiotic. 2 In search of selective methods to modify oligomycin A (1), we carried out bromination of (1) with NBS in DMF at neutral pH; this procedure yielded a mono-bromo derivative (2) in 45% yield (Figure 1 ). NMR studies showed the presence of a single bond C 16 -C 17 (instead of the double bond in (1) and a tetrahydropyrane cycle due to the formation of C 13 H-O-C 17 H bond confirmed by a low field shift of C 13 (DB10 p.p.m.) in comparison with 13 C NMR spectrum of (1) (81.73 and 72.15 p.p.m. for C 13 in (1) and (2), respectively) ( Table 1) . 2 The tetrahydropyrane ring contains Br in position C 16 . The spin coupling constants in the tetrahydropyrane ring correlate with 'chair' conformation and correspond to the following orientation of hydrogen atoms: C 13 H eq , C 14 H eq , C 16 H ax and C 17 H ax . On the basis of these coupling constant values and taking in mind that oligomycin A moiety has 13S and 14R configuration, 3 we can ascribe 13S, 14R, 16R and 17S stereochemistry to bromooligomycin (2) . This structure represents a new skeleton in this type of antibiotics.
The NMR spectra were elucidated using homo 1 H, 1 H (2D COSY) and hetero 1 H, 13 C (2D HETCOR) correlation as well as 1 H and 13 C 1D spectra of (1) and its derivatives and were registered using unity +400 (Varian, Palo Alto, CA, USA) spectrometer at 400.0 MHz for 1 H nuclei, and at 100.6 MHz for 13 C nuclei. The structure of (2) is membranous; a membranous structure has been demonstrated also for the product of the interaction of (1) with hydroxylamine. 2 It is likely that the formation of such structures is typical for this 26-membered macrolide as well as for 14-membered antibacterial macrolides (for example, erythromycin and its derivatives). 4 Bromo-oligomycin A (2) was low cytotoxic against HCT116 human colon cancer cell line and K562 human leukemia cell line (IC 50 16.0 ± 2.2 and 9.0 ± 1.4 mM, respectively), whereas the parental compound (1) was significantly more potent (IC 50 3.3±1.0 and 3.0±1.0 mM, respectively) as determined by MTT-test after a 72 h incubation. 5 Furthermore, (2) was weakly active against Streptomyces fradiae strain that is extremely sensitive to (1) (250 nM per disk and 0.001 nM per disk, respectively).
NBS
A lowered potency of (2) for actinobacterial cells correlated with a decreased activity against filamentous fungi (moulds) and yeast. (2) revealed the activity only against C. humicolus (MIC 2 mg ml À1 ), whereas for other studied fungi and yeast strains (2) was practically inert (MIC 416 mg ml À1 ). Determination of MICs was carried out according to NCCLS, Standards M27-A and M38-A. 6, 7 Low biological activities of compound (2) may be explained by distorted conformation of oligomycin A derivative in comparison with the starting antibiotic due to the formation of the webbed structure and also by the absence of free 13-OH group that participates at the interaction with oligomycin A target in cells. It was supposed that in oligomycins the hydroxyl groups could function as donors or acceptors of hydrogen bonds. 8 
EXPERIMENTAL PROCEDURE
Oligomycin A ((1); purity 95 %) was obtained in the Research Center for Biotechnology of Antibiotics BIOAN, Moscow using the Streptomyces avermitilis NIC B62 strain (production of (1) B1 g l À1 ). Fermentation was performed for 8 days at 281C in liquid medium. Isolation and purification involved the extraction with acetone-hexane mixture followed by crystallization.
Synthesis of bromo-oligomycin A (2).
To a solution of (1) (1.0 g, 1.3 mmol) in dry DMF (10 ml) N-Br-succinimide (1-bromopyrrolidine-2,5-dione) (0.25 g, 1.41 mmol) was added, the reaction mixture was stirred at room temperature for 2 h and analyzed by TLC in CHCl 3 -MeOH (10 : 0.5). The mixture was diluted with water; the reaction product was extracted with toluene, washed and dried over Na 2 SO 4 . Then the reaction product was purified by column chromatography on silica gel 60 (Merck) in CHCl 3 -MeOH (50 : 0.5) to give 0.45 g (45%) of (2) 
